Connective Tissue Disease-Associated Interstitial Lung Disease: a Disease Worthy of Great Attention
-
摘要: 结缔组织病(connective tissue disease, CTD)是以自身免疫及其介导的器官系统损伤为特征的一组全身性疾病。肺部并发症是CTD的重要关节外表现, 也是CTD患者死亡的主要原因。临床管理CTD相关间质性肺疾病(CTD-associated interstitial lung disease, CTD-ILD)的关键是确定ILD类型、疾病所处阶段、应给予何种治疗。目前CTD-ILD仍采用特发性间质性肺炎分类, 其诊断治疗尚无统一的临床指导策略。越来越多的研究发现, 自身抗体与CTD-ILD相关, 对临床诊治具有一定指导意义, 临床实践中应更多关注那些肺部表现不明显的CTD患者, 以尽早识别CTD-ILD, 给予适当治疗, 延缓疾病进展。
-
关键词:
- 结缔组织病 /
- 间质性肺疾病 /
- 结缔组织病相关间质性肺疾病
Abstract: Connective tissue disease (CTD) is a group of systemic disorder characterized by autoimmunity and autoimmune-mediated organ and system damage. The pulmonary complication is an important extra-articular feature of CTD and a major cause of mortality. The key point in the management of CTD-associated interstitial lung disease (CTD-ILD) should focus on the type of ILD, the stage of the disease, and what proper measures should be taken. CTD-ILD is still using the classification of idiopathic interstitial pneumonia. However, there is no authoritative clinical guidance for the diagnosis and treatment of CTD-ILD. More and more studies show that some auto-antibodies are strongly associated with CTD-ILD, which may guide clinical practice. In clinical practice, physicians should particularly pay more attention to CTD patients with insignificant pulmonary manifestations, so as to identify CTD-ILD in the early stage and intervene at the right time to delay the progression. -
[1] Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement:update on the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med, 2013, 188:733-748. doi: 10.1164/rccm.201308-1483ST [2] Wells AU, Denton CP. Interstitial lung disease in connective tissue disease-mechanisms and management[J]. Nat Rev Rheumatol, 2014, 10:728-739. doi: 10.1038/nrrheum.2014.149 [3] 张奉春.弥漫性结缔组织病的肺间质病变[J].中华临床免疫和变态反应杂志, 2008, 2:171-172. doi: 10.3969/j.issn.1673-8705.2008.03.001 [4] Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome[J]. Am J Respir Crit Care Med, 2002, 165:1581-1586. doi: 10.1164/rccm.2106012 [5] Ueda T, Sakagami T, Kikuchi T, et al. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis[J]. Respir Investig, 2018, 56:14-20. doi: 10.1016/j.resinv.2017.11.004 [6] Karampitsakos T, Tzouvelekis A, Chrysikos S, et al. Pulmonary hypertension in patients with interstitial lung disease[J]. Pulm Pharmacol Ther, 2018, pii: S1094-5539(17)30242-0. http://www.sciencedirect.com/science/article/pii/S1094553917302420 [7] Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis results from an inception cohort[J]. Rheumatology (Oxford), 2010, 49:1483-1489. doi: 10.1093/rheumatology/keq035 [8] Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relation to outcome[J]. Eur Respir J, 2011, 37:1411-1417. doi: 10.1183/09031936.00019210 [9] Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis[J]. Ann Rheum Dis, 2004, 63:297-301. doi: 10.1136/ard.2003.006122 [10] Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyo-sitis-dermatomyositis-associated interstitial lung disease[J]. Am J Respir Crit Care Med, 2001, 164:1182-1185. doi: 10.1164/ajrccm.164.7.2103110 [11] Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome[J]. Chest, 2006, 130:1489-1495. doi: 10.1378/chest.130.5.1489 [12] Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren's syndrome:a clinical, radiologic, and pathologic study[J]. Am J Respir Crit Care Med, 2005, 171:632-638. doi: 10.1164/rccm.200403-417OC [13] Bertoli AM, Vila LM, Apte M, et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVⅢ:factors predictive of pulmonary damage[J]. Lupus, 2007, 16:410-417. doi: 10.1177/0961203307079042 [14] Swigris JJ, Fischer A, Gillis J, et al. Pulmonary and thrombotic manifestations of systemic lupus erythematosus[J]. Chest, 2008, 133:271-280. doi: 10.1378/chest.07-0079 [15] Lee JS, Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease[J]. Expert Rev Clin Immunol, 2016, 12:509-520. doi: 10.1586/1744666X.2016.1139454 [16] Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis[J]. Rheumatology, 2016, 55:1906-1910. doi: 10.1093/rheumatology/kew224 [17] Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis[J]. Lung, 2009, 187:201-206. doi: 10.1007/s00408-009-9146-6 [18] Ball EM, Savage EM, Pendleton A. Refractory anti-synthetase syndrome treated with rituximab[J]. Rheumatology (Oxford), 2010, 49:1013. doi: 10.1093/rheumatology/kep438 [19] Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders[J]. Lancet, 2012, 380:689-698. doi: 10.1016/S0140-6736(12)61079-4 [20] Bonella F, Costabel U. Biomarkers in connective tissue disease associated interstitial lung disease[J]. Semin Respir Crit Care Med, 2014, 35:181-200. doi: 10.1055/s-0034-1371527 [21] 张亚妹, 彭清林, 卢昕, 等.抗PUF60抗体在中国特发性炎性肌病患者中的分布及临床意义[J].协和医学杂志, 2017, 4:244-250. doi: 10.3969/j.issn.1674-9081.2017.05.010
点击查看大图
计量
- 文章访问数: 407
- HTML全文浏览量: 73
- PDF下载量: 328
- 被引次数: 0